Patient-Initiated Consultations Beneficial in Psoriasis

Share this content:
Patient-Initiated Consultations Beneficial in Psoriasis
Patient-Initiated Consultations Beneficial in Psoriasis

THURSDAY, Feb. 1, 2018 (HealthDay News) -- For patients with psoriasis, a patient-initiated care consultation (PICC) intervention may offer clinical benefits compared with routine care, according to a study published online Jan. 24 in the British Journal of Dermatology.

Lina R. Khoury, from the Herlev and Gentofte Hospital in Denmark, and colleagues conducted a prospective trial involving patients with psoriasis in a dermatology outpatient clinic. One hundred fifty patients were randomized to the PICC group, where they participated in one annual consultation with a dermatologist and were able to initiate consultations as necessary, or to routine care, with a consultation every 12 to 16 weeks.

The researchers found that there was no statistically significant mean difference between the groups in Dermatology Life Quality Index (0.28; 95 percent confidence interval, −0.35 to 0.9) or Psoriasis Area Severity Index (−0.24; 95 percent confidence interval, −0.84 to 0.36) at week 52. PICC group patients requested 63.1 percent fewer dermatologist consultations (mean, 2.5±0.1 versus 5.1±0.6). Equal patient adherence and safety with treatment monitoring was seen between the groups; those in the PICC group were significantly better at attending consultations than those in the control group.

"PICC offers additional clinical benefits compared to routine care, making patients less dependent on clinical visits," the authors write. "The intervention adds no harm to monitoring systemic treatment and patients report high quality of life and satisfaction with healthcare."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »